Loading clinical trials...

A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging | Clinical Trials | Clareo Health

RECRUITINGNA

A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging

[68Ga]Pentixafor PET/CT for Staging of Hematological Malignancies: Comparison to [18F]FDG PET/CT

NCT06834412•Xijing Hospital

View on ClinicalTrials.gov

Summary

This is a prospective, open-label, single-center clinical study targeting hematological malignancies. 120 patients with a confirmed by pathology of non-Hodgkin's lymphoma or myeloma were included. Qualified subjects will undergo 18F-FDG PET/CT and 68Ga-Pentixafor PET/CT examination. The aim is to To investigate whether 68Ga-pentixafor PET imaging can be used as a reliable complement to 18F-FDG PET imaging for clinical staging, treatment response evaluation, and re-staging of patients with hematological malignancies.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Ages 18 to 75 years old Confirmed by pathology with NHLs or myeloma Willing and able to follow the study protocol.

Exclusion Criteria

•Children, pregnant or lactating women Severely impaired liver and kidney function (alanine aminotransferase \> 8-10 times the upper limit of normal, serum creatinine 186-442 umol/L) With a history of allergy to contrast media or other drugs

Locations (1)

Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University

Xi'an, Shaanxi, China

Key Dates

Start Date

November 3, 2021

Primary Completion Date

June 1, 2025

Completion Date

December 1, 2025

Last Updated

March 3, 2025

Enrollment

120

ESTIMATED participants

Conditions

Hematological Malignancies

Interventions

68Ga-Pentixafor and 18F-FDG PET/CT Scan

DIAGNOSTIC_TEST

Contacts

Ying Guo

CONTACT

0086+15991459177 guoying01192022@163.com

Xuebing Yu

CONTACT

0086+18967285780 786979204@qq.com

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592

Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic Syndromes+6 more

View study

RECRUITING

18F-Pentixafor PET in Hematologic Malignancies

NCT07122674

Hematological Malignancies

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging

Inclusion Criteria

Exclusion Criteria

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

18F-Pentixafor PET in Hematologic Malignancies

Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)

Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Cologne Cohort of Neutropenic Patients (CoCoNut)